Please read this notice and click the acknowledgement at the bottom of the page to continue.

Intended Audience:
This symposium is designed for Primary Care Physicians | Cardiologists | Hypertension Specialists Internists with Cardiology Specialty Focus | Preventive Medicine Specialists Endocrinologists | Diabetologists | Nurse Practitioners Geriatricians Endocrinologists | Pharmacists | Physician Assistants

Registration:
Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified symposium and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:
Supported by an independent educational grant from Pfizer, Inc.

Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Paul M. Ridker, MD
Grant/Research : Astra-Zeneca, Bayer, BMS, Dade-Behring, Novartis, Pharmacia, Roche, Sanofi-Aventis, VariagenicsConsultant: Schering Plough, Sanofi-Aventis, Astra-Zeneca, Isls Pharmaceutical, Dade-Behring

Scott Kinlay, MBBS, PhD
Grant/Research: Pfizer
Consultant: Pfizer
Speaker’s Bureau: Pfizer, Merck, Merck/Schering

L. Michael Prisant, MD, FACP, FACC, FAHA
Grant/Research: Astra-Zeneca, Novartis, Boerhinger-Ingelheim, Eli-Lilly
Consultant: Astra-Zeneca, Abbott, CV Therapeutics, Merck, Merck/Schering-Plough, Novartis, Reliant, Schwarz, SunTech MedicalSpeaker’s Bureau: Astra-Zeneca, Merck, Merck/Schering-Plough, Boehringer-Ingelheim, Novartis l

Christopher B. Granger, MD
Grant/Research: Astra-Zeneca, Proctor & Gamble, Alexion, Sanofi-Aventis, Novartis, Boehringer-Ingelheim, Genentech, Berlex, GSK, Bristol Myer Squibb

Program Faculty:

Christopher B. Granger, MD
Associate Professor of Medicine
Director, Cardiac Care Unit
Duke University Medical Center

Scott Kinlay, MBBS., PhD.
VAMC West Roxbury
Brigham & Women’s Hospital
Harvard Medical School

L. Michael Prisant, MD, FACP, FACC, FAHA
Professor of Medicine
Medical College of Georgia
Director of Hypertension & Lipid Clinic

Paul M Ridker, MD
Eugene Braunwald Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Boston, MA

Educational Objectives:

• Educate physicians and healthcare providers (HCPs) about recent landmark clinical trials focusing on cardiovascular and cerebrovascular disease protection, and how to apply the results of such trials and national association/academy/society guidelines for CV risk factor modification to clinical practice

• Educate physicians in strategies that maximize CV and cerebrovascular outcomes based on parameters addressing the issues of who, when, with what, and how long to treat patients with dyslipidemia and additional risk factors

• Educate physicians in evidence-directed use of statins in order to maximize cardiovascular and cerebrovascular outcomes

• Educate physicians and increase their awareness of the importance of bringing patients with dyslipidemia to established target goals established by governmental bodies (CDC, NHBLI) and professional medical organizations (AHA, ACC, NCEP and others) in order to optimize protection against adverse cardiovascular events

• Educate physicians and increase their awareness of the importance and efficacy of lipid-lowering agents—and call their attention to special considerations—in dyslipidemic patients who have additional risk factors, among them: diabetes, hypertension, coronary heart disease, smoking, strong family history of heart disease, obesity, history of stroke and other risk factors

• Educate physicians about clinical trials supporting safety and efficacy of lipid-lowering therapy in patients with diabetes, high blood pressure, and CHD

• Educate physicians in strategies that will assist them in measuring the benefit-to-risk ratio for statin therapy in multiple patient populations

• Educate physicians in strategies that will maximize adherence to lipid-lowering therapy and how to monitor potential side effects associated with lipid-lowering therapy

• Educate physicians about the possible impact of noncompliance with lipid-lowering therapy and the impact that poor adherence may have on CV outcomes

• Educate physicians on who, when, and how to screen for dyslipidemia, and how to risk stratify patients according to their lipid profiles and the existence of additional risk factors

Copyright (c) 2006 All rights reserved including

I have read the CME information statement

I have not read the CME information statement